Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | See Remarks | July 06, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date July 06, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,841 |
Reported balance
After 2026-07-06 transaction · row 1
1 source rowRow 1 · 2026-07-06 · Sale · Disposed 8,460 · Balance 196,841 F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 9, 2026 00:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 8,460 | $8.26 | $69,904.98 |
DisclosureSEC source: 0001437749-26-023078 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,841 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 01:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 70,321 | $0.00 Strike: $6.68 | $0.00 |
DisclosureSEC source: 0001437749-26-004947 · rdgdoc.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,321 Underlying: Common Stock · 70,321 shares Expires 2036-02-17 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 01:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 49,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-004947 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,301 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date. F1 · price: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 01:15 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 5,014 | $5.88 | $29,477.31 |
DisclosureSEC source: 0001437749-26-000922 · rdgdoc.xml · nonDerivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,907 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:15 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 3,973 | $5.84 | $23,218.21 |
DisclosureSEC source: 0001437749-26-000922 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,921 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 00:52 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 3,443 | $3.54 | $12,171.01 |
DisclosureSEC source: 0001437749-25-022549 · rdgdoc.xml · nonDerivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,894 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:52 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 4,374 | $3.53 | $15,453.34 |
DisclosureSEC source: 0001437749-25-022549 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,337 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 23:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 66,604 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001437749-25-003456 · rdgdoc.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,604 Underlying: Common Stock · 66,604 shares Expires 2035-02-06 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 23:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 48,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003456 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,711 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 00:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 8,633 | $3.15 | $27,208.63 |
DisclosureSEC source: 0001437749-25-000361 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,594 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.2101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 22:57 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 3,637 | $3.70 | $13,460.90 |
DisclosureSEC source: 0001437749-24-023017 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,227 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.6001 to $3.8901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 01:15 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 4,349 | $3.27 | $14,214.71 |
DisclosureSEC source: 0001437749-24-022063 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,864 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2601 to $3.3101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:54 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 52,452 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001437749-24-004207 · rdgdoc.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,452 Underlying: Common Stock · 52,452 shares Expires 2034-02-11 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:54 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 37,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004207 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,213 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 23:42 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 8,358 | $4.49 | $37,493.15 |
DisclosureSEC source: 0001437749-24-000765 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,319 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.3601 to $4.7101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 23:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 7,809 | $3.31 | $25,857.16 |
DisclosureSEC source: 0001437749-23-019521 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,677 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:44 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 66,864 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001437749-23-003375 · rdgdoc.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,864 Underlying: Common Stock · 66,864 shares Expires 2033-02-09 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:44 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 48,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003375 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,486 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 4,225 | $4.18 | $17,651.63 |
DisclosureSEC source: 0001437749-23-000521 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,350 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.1922, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:32 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 429 | $4.50 | $1,929.56 |
DisclosureSEC source: 0001437749-22-028559 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,575 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.4601 to $4.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 429 | $2.25 | $965.25 |
DisclosureSEC source: 0001437749-22-026041 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,004 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 435 | $2.34 | $1,015.90 |
DisclosureSEC source: 0001437749-22-023677 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,433 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.33 to $2.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:40 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 433 | $2.59 | $1,121.30 |
DisclosureSEC source: 0001437749-22-021984 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,868 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.565 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 22:48 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 429 | $2.89 | $1,239.81 |
DisclosureSEC source: 0001437749-22-018960 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,301 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| July 05, 2022 Filed Jul 8, 2022 00:41 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 3,753 | $2.63 | $9,876.02 |
DisclosureSEC source: 0001437749-22-016854 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,730 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:03 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 417 | $1.94 | $810.69 |
DisclosureSEC source: 0001437749-22-014432 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,483 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 438 | $2.31 | $1,011.82 |
DisclosureSEC source: 0001437749-22-011162 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,900 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 413 | $3.08 | $1,271.21 |
DisclosureSEC source: 0001437749-22-008330 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,338 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 14, 2022 23:43 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 32,353 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001437749-22-006190 · rdgdoc.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,353 Underlying: Common Stock · 32,353 shares Expires 2032-03-02 F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| March 03, 2022 Filed Mar 14, 2022 23:43 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 22,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-006190 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,751 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:11 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 446 | $2.26 | $1,009.43 |
DisclosureSEC source: 0001437749-22-005303 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,104 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:38 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 533 | $2.47 | $1,317.36 |
DisclosureSEC source: 0001437749-22-002423 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,550 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:03 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 3,707 | $3.21 | $11,889.83 |
DisclosureSEC source: 0001437749-22-000465 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,083 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.19 to $3.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 01:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 441 | $2.90 | $1,278.90 |
DisclosureSEC source: 0001437749-21-027964 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,790 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 22:20 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 427 | $5.64 | $2,408.71 |
DisclosureSEC source: 0001209191-21-062781 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,231 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 21:15 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 443 | $6.15 | $2,725.82 |
DisclosureSEC source: 0001437749-21-023377 · rdgdoc.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,658 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 19:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 422 | $7.52 | $3,173.86 |
DisclosureSEC source: 0001209191-21-054951 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,101 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 21:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 420 | $7.53 | $3,160.54 |
DisclosureSEC source: 0001209191-21-049429 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,523 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:40 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,016 | $9.15 | $9,297.72 |
DisclosureSEC source: 0001209191-21-045596 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,943 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.14 to $9.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 416 | $10.77 | $4,480.94 |
DisclosureSEC source: 0001209191-21-038292 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,959 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.7510 to $10.8000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:39 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 417 | $9.91 | $4,132.64 |
DisclosureSEC source: 0001209191-21-030347 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,375 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 426 | $9.80 | $4,176.04 |
DisclosureSEC source: 0001209191-21-025728 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,792 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:43 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 422 | $10.16 | $4,288.28 |
DisclosureSEC source: 0001209191-21-017839 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,218 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 27,793 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001209191-21-012529 · doc4.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,793 Underlying: COMMON STOCK · 27,793 shares Expires 2031-02-16 F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to (i) one-third (1/3) of the Shares (as defined in the Plan) underlying the Option on the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012529 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,640 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to (i) one-third (1/3) of the Restricted Stock Units on the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| February 17, 2021 Filed Feb 24, 2021 22:12 UTC Amendment | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 27,793 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001209191-21-013891 · doc4a.xml · derivative · entry 2 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,793 Underlying: COMMON STOCK · 27,793 shares Expires 2031-02-16 F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to (i) one-third (1/3) of the Shares (as defined in the Plan) underlying the Option on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024. Read SEC document |
| February 17, 2021 Filed Feb 24, 2021 22:12 UTC Amendment | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013891 · doc4a.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,640 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to (i) one-third (1/3) of the Restricted Stock Units on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 23:47 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 412 | $12.27 | $5,053.72 |
DisclosureSEC source: 0001209191-21-007483 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,883 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2607 to $12.2745, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:42 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 6,463 | $10.23 | $66,144.93 |
DisclosureSEC source: 0001209191-21-002333 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,295 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.1601 to $10.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 572 | $10.69 | $6,111.82 |
DisclosureSEC source: 0001209191-20-041359 · doc4.xml · nonDerivative · entry 1 HUNT DOUGLAS M · CIK 0001727172 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,758 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.